Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe?
作者信息
Miyake Hideaki
机构信息
Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S347. doi: 10.21037/atm.2019.09.106.
Abstract
摘要
相似文献
1
Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe?
Ann Transl Med. 2019 Dec;7(Suppl 8):S347. doi: 10.21037/atm.2019.09.106.
2
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
J Urol. 2011 Jan;185(1):60-6. doi: 10.1016/j.juro.2010.09.012. Epub 2010 Nov 12.
3
The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.
J Urol. 2007 Jun;177(6):1978-84. doi: 10.1016/j.juro.2007.01.136.
4
Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
Chin Med J (Engl). 2016 Mar 5;129(5):530-5. doi: 10.4103/0366-6999.177001.
5
The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.
Curr Opin Urol. 2019 Sep;29(5):531-539. doi: 10.1097/MOU.0000000000000663.
6
Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
J Urol. 2018 Sep;200(3):528-534. doi: 10.1016/j.juro.2018.03.077. Epub 2018 Mar 21.
7
The role of cytoreductive surgery in the era of targeted agents.
Curr Opin Urol. 2015 Sep;25(5):374-80. doi: 10.1097/MOU.0000000000000192.
8
Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
Jpn J Clin Oncol. 2015 Jan;45(1):96-102. doi: 10.1093/jjco/hyu171. Epub 2014 Oct 23.
9
Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Curr Opin Urol. 2019 Sep;29(5):521-525. doi: 10.1097/MOU.0000000000000661.
10
Role of cytoreductive nephrectomy in renal cell carcinoma.
Future Oncol. 2009 Aug;5(6):859-69. doi: 10.2217/fon.09.52.
本文引用的文献
1
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
Eur Urol. 2019 Oct;76(4):437-440. doi: 10.1016/j.eururo.2019.06.006. Epub 2019 Jun 18.
2
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543.
3
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.
Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.
4
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.
5
Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
Int J Clin Oncol. 2018 Jun;23(3):553-558. doi: 10.1007/s10147-017-1232-9. Epub 2018 Jan 13.
6
Systemic therapy in metastatic renal cell carcinoma.
World J Urol. 2017 Feb;35(2):179-188. doi: 10.1007/s00345-016-1868-5. Epub 2016 Jun 9.
7
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
JAMA Oncol. 2016 Oct 1;2(10):1303-1309. doi: 10.1001/jamaoncol.2016.1197.
8
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.
9
Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Clin Genitourin Cancer. 2014 Oct;12(5):373-83. doi: 10.1016/j.clgc.2014.03.012. Epub 2014 Mar 27.
10
Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.
Urol Int. 2012;89(1):83-8. doi: 10.1159/000338057. Epub 2012 May 16.
Zotero 插件